Stocks Comparison
Idexx Laboratories vs Intellia Therapeutics: revenue, profit, margins and growth compared
Idexx Laboratories brought in $4.3B of revenue in fiscal 2025, Intellia Therapeutics $67.7M in fiscal 2025. Revenue changed by +10.4% at Idexx Laboratories and +16.9% at Intellia Therapeutics on the year before, so Intellia Therapeutics grew faster. Idexx Laboratories kept 24.6% of its revenue as net profit, Intellia Therapeutics -609.9%. Free cash flow was $1.1B at Idexx Laboratories and -$395.9M at Intellia Therapeutics.
Side by side, latest fiscal year
| IDXX | NTLA | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $4.3B | $67.7M |
| Revenue growth | +10.4% | +16.9% |
| Net income | $1.1B | -$412.7M |
| Net margin | 24.6% | -609.9% |
| Free cash flow | $1.1B | -$395.9M |
| Free cash flow margin | 24.6% | -585.0% |
| Earnings per share (diluted) | $13.08 | -$3.81 |
| Cash | $180.1M | $155.5M |
| Debt | $450M | n/a |
| Price to earnings | 39.7 | n/a |
| Market value | $40.9B | $1.6B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #67 of 523 · Health care | #339 of 523 · Health care |
Over the years
Questions about Idexx Laboratories and Intellia Therapeutics
Which is bigger by revenue, Idexx Laboratories or Intellia Therapeutics?
Idexx Laboratories is bigger by revenue: $4.3B in fiscal 2025, against $67.7M for Intellia Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Idexx Laboratories or Intellia Therapeutics?
Idexx Laboratories had a net margin of 24.6% in fiscal 2025; Intellia Therapeutics had -609.9% in fiscal 2025.
Which grew revenue faster, Idexx Laboratories or Intellia Therapeutics?
In their latest fiscal years revenue changed by +10.4% at Idexx Laboratories and +16.9% at Intellia Therapeutics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.